Advertisement

Physiological Correlates of Premenstrual Dysphoric Disorder (PMDD)

  • Inger Sundström PoromaaEmail author
Chapter
Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 21)

Abstract

Premenstrual dysphoric disorder (PMDD) is a mood disorder with onset of functionally impairing or distressing mood symptoms in the late luteal phase of the menstrual cycle. Psychophysiologic findings in PMDD broadly fall into two categories: vulnerability trait findings, thus categorized because they are present in the asymptomatic phases of the menstrual cycle, and state findings, which are only present in the symptomatic late luteal phase and which are potentially representative of the hormonal events and biological mechanisms that lead to PMDD. Trait vulnerability markers in PMDD include diminished cardiovascular stress responses, lower heart rate variability (reflecting increased vagal tone), and lower P300 amplitude, eventually suggesting that women with PMDD share a number of physiological correlates with related anxiety and mood disorders. State findings in PMDD include lower luteal phase prepulse inhibition and altered luteal phase emotion processing. Lower prepulse inhibition in the late luteal phase may be an important ovarian steroid-influenced indicative of altered serotonergic neurotransmission, of relevance for women with PMDD. Attempts to determine the neural correlates of emotion processing in the late luteal phase are thus far inconsistent, but promising.

Keywords

Premenstrual dysphoric disorder Estradiol Progesterone Prepulse inhibition Emotion processing Functional magnetic resonance imaging 

References

  1. Andreano JM, Cahill L (2010) Menstrual cycle modulation of medial temporal activity evoked by negative emotion. Neuroimage 53:1286–1293Google Scholar
  2. Andreen L, Bixo M, Nyberg S et al (2003) Progesterone effects during sequential hormone replacement therapy. Eur J Endocrinol 148:571–577Google Scholar
  3. Andreen L, Sundstrom-Poromaa I, Bixo M et al (2005) Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone. Psychoneuroendocrino 30:212–224Google Scholar
  4. Andreen L, Sundstrom-Poromaa I, Bixo M et al (2006) Allopregnanolone concentration and mood–a bimodal association in postmenopausal women treated with oral progesterone. Psychopharmacology (Berl) 187:209–221Google Scholar
  5. Backstrom T, Andersson A, Andree L et al (2003) Pathogenesis in menstrual cycle-linked CNS disorders. Ann N Y Acad Sci 1007:42–53Google Scholar
  6. Backstrom T, Bixo M, Johansson M et al (2014) Allopregnanolone and mood disorders. Prog Neurobiol 113:88–94Google Scholar
  7. Baker FC, Colrain IM (2010) Daytime sleepiness, psychomotor performance, waking EEG spectra and evoked potentials in women with severe premenstrual syndrome. J Sleep Res 19:214–227Google Scholar
  8. Baker FC, Colrain IM, Trinder J (2008) Reduced parasympathetic activity during sleep in the symptomatic phase of severe premenstrual syndrome. J Psychosom Res 65:13–22Google Scholar
  9. Baller EB, Wei SM, Kohn PD et al (2013) Abnormalities of dorsolateral prefrontal function in women with premenstrual dysphoric disorder: a multimodal neuroimaging study. Am J Psychiatry 170:305–14Google Scholar
  10. Bannbers E, Gingnell M, Engman J et al (2012) The effect of premenstrual dysphoric disorder and menstrual cycle phase on brain activity during response inhibition. J Affect Disord 142:347–350Google Scholar
  11. Bannbers E, Kask K, Wikstrom J et al (2011) Patients with premenstrual dysphoric disorder have increased startle modulation during anticipation in the late luteal phase period in comparison to control subjects. Psychoneuroendocrino 36:1184–1192Google Scholar
  12. Bixo M, Andersson A, Winblad B et al (1997) Progesterone, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-5alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res 764:173–178Google Scholar
  13. Bixo M, Backstrom T, Winblad B et al (1995) Estradiol and testosterone in specific regions of the human female brain in different endocrine states. J Steroid Biochem Mol Biol 55:297–303Google Scholar
  14. Bixo M, Backstrom T, Winblad B et al (1986) Comparison between pre- and postovulatory distributions of oestradiol and progesterone in the brain of the PMSG-treated rat. Acta Physiol Scand 128:241–246Google Scholar
  15. Borgstrom A, Kask K, Gulinello M et al (2008) Patients with adverse mood effects from combined oral contraceptives have lower levels of prepulse inhibition than healthy controls. Psychoneuroendocrino 33:487–496Google Scholar
  16. Brinton RD, Thompson RF, Foy MR et al (2008) Progesterone receptors: form and function in brain. Front Neuroendocrinol 29:313–339Google Scholar
  17. Brown J, O’Brien PM, Marjoribanks J et al (2009) Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev CD001396Google Scholar
  18. Byrnes EM, Bridges RS, Scanlan VF et al (2007) Sensorimotor gating and dopamine function in postpartum rats. Neuropsychopharmacolog 32:1021–1031Google Scholar
  19. Cajochen C, Krauchi K, Wirz-Justice A (1997) The acute soporific action of daytime melatonin administration: effects on the EEG during wakefulness and subjective alertness. J Biol Rhythms 12:636–643Google Scholar
  20. Charitidi K, Meltser I, Canlon B (2012) Estradiol treatment and hormonal fluctuations during the estrous cycle modulate the expression of estrogen receptors in the auditory system and the prepulse inhibition of acoustic startle response. Endocrinology 153:4412–4421Google Scholar
  21. de Zambotti M, Nicholas CL, Colrain IM et al (2013) Autonomic regulation across phases of the menstrual cycle and sleep stages in women with premenstrual syndrome and healthy controls. Psychoneuroendocrinology 38:2618–2627Google Scholar
  22. Ehlers CL, Phillips E, Parry BL (1996) Electrophysiological findings during the menstrual cycle in women with and without late luteal phase dysphoric disorder: relationship to risk for alcoholism? Biol Psychiatry 39:720–732Google Scholar
  23. Epperson CN, Haga K, Mason GF et al (2002) Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 59:851–858Google Scholar
  24. Epperson CN, Pittman B, Czarkowski KA et al (2007) Luteal-phase accentuation of acoustic startle response in women with premenstrual dysphoric disorder. Neuropsychopharmacology 32:2190–2198Google Scholar
  25. Etkin A, Wager TD (2007) Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry 164:1476–1488Google Scholar
  26. Freeman EW, Schweizer E, Rickels K (1995) Personality factors in women with premenstrual syndrome. Psychosom Med 57:453–459Google Scholar
  27. Gingnell M, Ahlstedt V, Bannbers E et al (2014) Social stimulation and corticolimbic reactivity in premenstrual dysphoric disorder: a preliminary study. Biol Mood Anxiety Disord 4:3Google Scholar
  28. Gingnell M, Bannbers E, Wikstrom J et al (2013) Premenstrual dysphoric disorder and prefrontal reactivity during anticipation of emotional stimuli. Eur Neuropsychopharmacol 23:1474–1483Google Scholar
  29. Gingnell M, Comasco E, Oreland L et al (2010) Neuroticism-related personality traits are related to symptom severity in patients with premenstrual dysphoric disorder and to the serotonin transporter gene-linked polymorphism 5-HTTPLPR. Arch Womens Ment Health 13:417-423Google Scholar
  30. Gingnell M, Morell A, Bannbers E et al (2012) Menstrual cycle effects on amygdala reactivity to emotional stimulation in premenstrual dysphoric disorder. Horm Behav 62:400–406Google Scholar
  31. Girdler SS, Leserman J, Bunevicius R et al (2007) Persistent alterations in biological profiles in women with abuse histories: influence of premenstrual dysphoric disorder. Health Psychol 26:201–213Google Scholar
  32. Girdler SS, Pedersen CA, Stern RA et al (1993) Menstrual cycle and premenstrual syndrome: modifiers of cardiovascular reactivity in women. Health Psychol 12:180–192Google Scholar
  33. Girdler SS, Pedersen CA, Straneva PA et al (1998) Dysregulation of cardiovascular and neuroendocrine responses to stress in premenstrual dysphoric disorder. Psychiatry Res 81:163–178Google Scholar
  34. Girdler SS, Sherwood A, Hinderliter AL et al (2003) Biological correlates of abuse in women with premenstrual dysphoric disorder and healthy controls. Psychosom Med 65:849–856Google Scholar
  35. Girdler SS, Straneva PA, Light KC et al (2001) Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry 49:788–797Google Scholar
  36. Gogos A, Kwek P, Chavez C et al (2010) Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors. J Pharmacol Exp Ther 333:218–227Google Scholar
  37. Gogos A, Kwek P, den Buuse M (2012) The role of estrogen and testosterone in female rats in behavioral models of relevance to schizophrenia. Psychopharmacology (Berl) 219:213–224Google Scholar
  38. Gogos A, Martin S, Jones ME et al (2006a) Oestrogen modulation of the effect of 8-OH-DPAT on prepulse inhibition: effects of aromatase deficiency and castration in mice. Psychopharmacology (Berl) 188:100–110Google Scholar
  39. Gogos A, Nathan PJ, Guille V et al (2006b) Estrogen prevents 5-HT1A receptor-induced disruptions of prepulse inhibition in healthy women. Neuropsychopharmacology 31:885–889Google Scholar
  40. Gogos A, Van den Buuse M (2004) Estrogen and progesterone prevent disruption of prepulse inhibition by the serotonin-1A receptor agonist 8-hydroxy-2-dipropylaminotetralin. J Pharmacol Exp Ther 309:267–274Google Scholar
  41. Gogos A, van den Buuse M, Rossell S (2009) Gender differences in prepulse inhibition (PPI) in bipolar disorder: men have reduced PPI, women have increased PPI. Int J Neuropsychopharmacol 12:1249–1259Google Scholar
  42. Goldstein JM, Jerram M, Abbs B et al (2010) Sex differences in stress response circuitry activation dependent on female hormonal cycle. J Neurosci 30:431–438Google Scholar
  43. Gruber CJ, Tschugguel W, Schneeberger C et al (2002) Production and actions of estrogens. N Engl J Med 346:340–352Google Scholar
  44. Grupe DW, Nitschke JB (2013) Uncertainty and anticipation in anxiety: an integrated neurobiological and psychological perspective. Nat Rev Neurosci 14:488–501Google Scholar
  45. Guerra-Araiza C, Cerbon MA, Morimoto S et al (2000) Progesterone receptor isoforms expression pattern in the rat brain during the estrous cycle. Life Sci 66:1743–1752Google Scholar
  46. Guerra-Araiza C, Coyoy-Salgado A, Camacho-Arroyo I (2002) Sex differences in the regulation of progesterone receptor isoforms expression in the rat brain. Brain Res Bull 59:105–109Google Scholar
  47. Guerra-Araiza C, Villamar-Cruz O, Gonzalez-Arenas A et al (2003) Changes in progesterone receptor isoforms content in the rat brain during the oestrous cycle and after oestradiol and progesterone treatments. J Neuroendocrinol 15:984–990Google Scholar
  48. Guille V, Gogos A, Nathan PJ et al (2011) Interaction of estrogen with central serotonergic mechanisms in human sensory processing: loudness dependence of the auditory evoked potential and mismatch negativity. J Psychopharmacol 25:1614–1622Google Scholar
  49. Gulinello M, Orman R, Smith SS (2003) Sex differences in anxiety, sensorimotor gating and expression of the alpha4 subunit of the GABAA receptor in the amygdala after progesterone withdrawal. Eur J Neurosci 17:641–648Google Scholar
  50. Gulinello M, Smith SS (2003) Anxiogenic effects of neurosteroid exposure: sex differences and altered GABAA receptor pharmacology in adult rats. J Pharmacol Exp Ther 305:541-548Google Scholar
  51. Hill RA, Wu YW, Gogos A et al (2013) Sex-dependent alterations in BDNF-TrkB signaling in the hippocampus of reelin heterozygous mice: a role for sex steroid hormones. J Neurochem 126:389–399Google Scholar
  52. Jovanovic H, Cerin A, Karlsson P et al (2006) A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res 148:185–193Google Scholar
  53. Kask K, Backstrom T, Gulinello M et al (2008a) Lower levels of prepulse inhibition of startle response in pregnant women compared to postpartum women. Psychoneuroendocrinology 33:100–107Google Scholar
  54. Kask K, Backstrom T, Lundgren P et al (2009) Allopregnanolone has no effect on startle response and prepulse inhibition of startle response in patients with premenstrual dysphoric disorder or healthy controls. Pharmacol Biochem Behav 92:608–613Google Scholar
  55. Kask K, Gulinello M, Backstrom T et al (2008b) Patients with premenstrual dysphoric disorder have increased startle response across both cycle phases and lower levels of prepulse inhibition during the late luteal phase of the menstrual cycle. Neuropsychopharmacology 33:2283–2290Google Scholar
  56. Kato J, Hirata S, Nozawa A et al (1994) Gene expression of progesterone receptor isoforms in the rat brain. Horm Behav 28:454–463Google Scholar
  57. Kendler KS, Karkowski LM, Corey LA et al (1998) Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry 155:1234–1240Google Scholar
  58. Kumari V (2011) Sex differences and hormonal influences in human sensorimotor gating: implications for schizophrenia. Curr Top Behav Neurosci 8:141–154Google Scholar
  59. Kumari V, Aasen I, Papadopoulos A et al (2008) A comparison of prepulse inhibition in pre- and postmenopausal women and age-matched men. Neuropsychopharmacology 33:2610–2618Google Scholar
  60. Kumari V, Konstantinou J, Papadopoulos A et al (2010) Evidence for a role of progesterone in menstrual cycle-related variability in prepulse inhibition in healthy young women. Neuropsychopharmacology 35:929–937Google Scholar
  61. Landen M, Erlandsson H, Bengtsson F et al (2009) Short onset of action of a serotonin reuptake inhibitor when used to reduce premenstrual irritability. Neuropsychopharmacology 34:585–592Google Scholar
  62. Landen M, Wennerblom B, Tygesen H et al (2004) Heart rate variability in premenstrual dysphoric disorder. Neuropsychopharmacology 29:733–740Google Scholar
  63. Lang PJ, Davis M (2006) Emotion, motivation, and the brain: reflex foundations in animal and human research. Prog Brain Res 156:3–29Google Scholar
  64. Lang PJ, Davis M, Ohman A (2000) Fear and anxiety: animal models and human cognitive psychophysiology. J Affect Disord 61:137–159Google Scholar
  65. Marjoribanks J, Brown J, O’Brien PM et al (2013) Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 6:CD001396Google Scholar
  66. Matsumoto T, Ushiroyama T, Kimura T et al (2007) Altered autonomic nervous system activity as a potential etiological factor of premenstrual syndrome and premenstrual dysphoric disorder. Biopsychosoc Med 1:24Google Scholar
  67. Melcangi RC, Panzica G, Garcia-Segura LM (2011) Neuroactive steroids: focus on human brain. Neuroscience 191:1–5Google Scholar
  68. O’Brien PM, Backstrom T, Brown C et al (2011) Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health 14:13–21Google Scholar
  69. Osterlund MK, Gustafsson JA, Keller E et al (2000a) Estrogen receptor beta (ERbeta) messenger ribonucleic acid (mRNA) expression within the human forebrain: distinct distribution pattern to ERalpha mRNA. J Clin Endocrinol Metab 85:3840–3846Google Scholar
  70. Osterlund MK, Keller E, Hurd YL (2000b) The human forebrain has discrete estrogen receptor alpha messenger RNA expression: high levels in the amygdaloid complex. Neuroscience 95:333–342Google Scholar
  71. Ottander U, Poromaa IS, Bjurulf E et al (2005) Allopregnanolone and pregnanolone are produced by the human corpus luteum. Mol Cell Endocrinol 239:37–44Google Scholar
  72. Perkonigg A, Yonkers KA, Pfister H et al (2004) Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry 65:1314–1322Google Scholar
  73. Pilver CE, Levy BR, Libby DJ et al (2011) Posttraumatic stress disorder and trauma characteristics are correlates of premenstrual dysphoric disorder. Arch Womens Ment Health 14:383–93Google Scholar
  74. Protopopescu X, Tuescher O, Pan H et al (2008) Toward a functional neuroanatomy of premenstrual dysphoric disorder. J Affect Disord 108:87–94Google Scholar
  75. Roberto M, Gilpin NW, Siggins GR (2012) The central amygdala and alcohol: role of gamma-aminobutyric acid, glutamate, and neuropeptides. Cold Spring Harb Perspect Med 2:a012195Google Scholar
  76. Sadler C, Smith H, Hammond J et al (2010) Lifestyle factors, hormonal contraception, and premenstrual symptoms: the United Kingdom Southampton women’s survey. J Womens Health (Larchmt) 19:391–396Google Scholar
  77. Schmidt PJ, Nieman LK, Danaceau MA et al (1998) Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 338:209–216Google Scholar
  78. Segebladh B, Bannbers E, Kask K et al (2011) Prevalence of violence exposure in women with premenstrual dysphoric disorder in comparison with other gynecological patients and asymptomatic controls. Acta Obstet Gynecol Scand 90:746–752Google Scholar
  79. Segebladh B, Borgstrom A, Nyberg S et al (2009) Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am J Obstet Gynecol 201(139): e1–8Google Scholar
  80. Shin LM, Liberzon I (2010) The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 35:169–191Google Scholar
  81. Sundstrom I, Backstrom T (1998) Patients with premenstrual syndrome have decreased saccadic eye velocity compared to control subjects. Biol Psychiatry 44:755–764Google Scholar
  82. Sundstrom Poromaa I, Smith S, Gulinello M (2003) GABA receptors, progesterone and premenstrual dysphoric disorder. Arch Women Ment Health 6:23–41Google Scholar
  83. Talledo JA, Sutherland Owens AN, Schortinghuis T et al (2009) Amphetamine effects on startle gating in normal women and female rats. Psychopharmacology (Berl) 204:165–175Google Scholar
  84. Thwaites SJ, van den Buuse MGogos A (2014) Differential effects of estrogen and testosterone on auditory sensory gating in rats. Psychopharmacology (Berl) 231:243–56Google Scholar
  85. Toufexis DJ, Davis C, Hammond A et al (2004) Progesterone attenuates corticotropin-releasing factor-enhanced but not fear-potentiated startle via the activity of its neuroactive metabolite, allopregnanolone. J Neurosci 24:10280–10287Google Scholar
  86. Toufexis DJ, Rochford J, Walker CD et al (1999) Lactation-induced reduction in rats’ acoustic startle is associated with changes in noradrenergic neurotransmission. Behav Neurosci 113:176–184Google Scholar
  87. Vaillancourt C, Cyr M, Rochford J et al (2002) Effects of ovariectomy and estradiol on acoustic startle responses in rats. Pharmacol Biochem Behav 74:103–109Google Scholar
  88. van den Akker O, Steptoe A (1989) Psychophysiological responses in women reporting severe premenstrual symptoms. Psychosom Med 51:319–328Google Scholar
  89. van den Buuse M, Eikelis N (2001) Estrogen increases prepulse inhibition of acoustic startle in rats. Eur J Pharmacol 425:33–41Google Scholar
  90. van Wingen GA, van Broekhoven F, Verkes RJ et al (2008) Progesterone selectively increases amygdala reactivity in women. Mol Psychiatry 13:325–333Google Scholar
  91. Wang M, Seippel L, Purdy RH et al (1996) Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5 alpha-pregnan-20-one. J Clin Endocrinol Metab 81:1076–1082Google Scholar
  92. Wittchen HU, Becker E, Lieb R et al (2002) Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 32:119–132Google Scholar
  93. Wittchen HU, Perkonigg A, Pfister H (2003) Trauma and PTSD—an overlooked pathogenic pathway for premenstrual dysphoric disorder? Arch Women Ment Health 6:293–297Google Scholar
  94. Wu YC, Hill RA, Gogos A et al (2013) Sex differences and the role of estrogen in animal models of schizophrenia: interaction with BDNF. Neuroscience 239:67–83Google Scholar
  95. Wyatt KM, Dimmock PW, Ismail KM et al (2004) The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis. BJOG 111:585–593Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Uppsala UniversityUppsalaSweden

Personalised recommendations